Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome
Streng, Bianca M M; Bont, Marin; Delemarre, Eveline M; Binnendijk, Rob S; Smit, Gaby; den Hartog, Gerco; Coppus, Antonia M W; de Vries, Esther; Weijerman, Michel E; Lamberts, Regina; de Graaf, Gert; van der Klis, Fiona R; Vidarsson, Gestur; Rave, Neele; Bont, Louis J; Wildenbeest, Joanne G
(2022) Journal of Infectious Diseases, volume 226, issue 4, pp. 673 - 677
(Article)
Abstract
UNLABELLED: The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this
... read more
prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348.
show less
Download/Full Text
Keywords: Adult, Antibodies, Viral, Antibody Formation, BNT162 Vaccine, COVID-19/prevention & control, COVID-19 Vaccines, Down Syndrome, Humans, Prospective Studies, RNA, Messenger, SARS-CoV-2, Vaccination
ISSN: 0022-1899
Publisher: Oxford University Press
Note: © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
(Peer reviewed)
